Tislelizumab Combined With Chemotherapy Versus Chemotherapy Alone in Recurrent or Metastatic Nasopharyngeal Cancer (NPC)

NCT03924986 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

263

Enrollment

INDUSTRY

Sponsor class

Conditions

Recurrent or Metastatic Nasopharyngeal Cancer

Interventions

DRUG: Tislelizumab
DRUG: Placebo
DRUG: Gemcitabine
DRUG: Cisplatin

Sponsor

BeiGene